NCT02498392View on ClinicalTrials.gov

An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress

PHASE2CompletedINTERVENTIONAL

Enrollment

161

Participants

Timeline

Start Date

October 7, 2015

Primary Completion Date

February 4, 2019

Study Completion Date

February 4, 2019

Conditions

Depressive DisorderAnxiety

Interventions

DRUG

JNJ-42165279

JNJ-42165279 will be administered orally at a dose of 25 milligrams (mg) tablet once daily for 6 weeks.

OTHER

Placebo

Matching Placebo will be administered orally.

Trial Locations (32)

Unknown

Costa Mesa

Oceanside

Miami

Natick

Cedarhurst

Raleigh

Allentown

Salt Lake City

Chisinau

Orenburg

Saint Petersburg

Saratov

Tomsk

Yekaterinburg

Alicante

Barcelona

Bilbao

Sant Boi de Llobregat

Zamora

Hlevakha

Kharkiv

Kherson

Kyiv

Lviv

Smila

Uzhhorod

Barnsley

Blackpool

Liverpool

Manchester

South Staffordshire

Stourton

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02498392 - An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress | Biotech Hunter | Biotech Hunter